At Takeda we believe that no gastrointestinal (GI) disease that is life-limiting to patients should remain unnoticed or untreated. With nearly 30 years of experience in gastroenterology, we have made significant strides in developing treatments for patients in areas of high unmet need by using cutting-edge technologies to discover and develop a sophisticated range of medicines. Our approach is a simple one: if there is a need, we will seek to meet it; if there is a patient, we will strive to find a viable treatment solution for them.
Takeda’s world-class R&D team has an unwavering commitment and passion for developing innovative therapies. We collaborate in areas where patients’ needs are greatest, forming partnerships that will enable us to make a greater impact in GI and on patients’ lives - now and in the future. Together with researchers, patient groups and more, Takeda is working to advance scientific research and clinical medicine and will continue to expand our R&D in search of better disease management for all those affected by GI and liver diseases.
Includes inflammatory bowel diseases like Ucerative Colitis and Crohn’s disease and all associated complications such as Perianal Fistulas, Short Bowel Syndrome and Intestinal Failure. Celiac disease and other gastrointestinal inflammatory diseases such as Eosinophilic Esophagitis are also included.
Including gastroparesis, nausea and vomiting, and rare enteric neuropathies.
Focusing on developing antifibrotics for diseases leading to late-stage liver fibrosis, complications of end-stage liver diseases, and select rare liver diseases.
